English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 July 2022, 18:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Berhad
Malaysian Genomics Proposes Private Placement
Group to use proceeds for future viable investment and purchase of equipment

PETALING JAYA, Malaysia, July 8, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later.

Azri Azerai, Executive Director of Malaysian Genomics Resource Centre Berhad

Shareholders had approved in the AGM convened on 30 November 2021 for the Group to issue and allot new shares at any time and at such price as the Board of Directors deemed fit provided the number of new shares does not exceed 10% of the total number of issued shares. The new placement shares will rank equally in all respects with existing Malaysian Genomics shares except they will not be entitled to any dividends, rights, allotments and any other forms of distribution should the entitlement date precede the relevant date of allotment and issuance of the new placement shares.

Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "We are proposing the private placement to raise funds mainly for the Group's future investments of which we are still exploring options and a part of the proceeds will be allocated for the purchase of equipment including IT hardware, biological safety cabinet and extraction automation for our existing and future businesses."

"The reopening of the economy presents opportunities in the private healthcare segment and the fresh funds raised will enable us to be able to take advantage of the possibilities. We diversified into the biopharmaceutical business in 2020 and have since been pushing to open channels for our cell therapies and genetic tests through a series of agreements that gives us a wider market reach. We also bought a 51% stake in a kidney dialysis operator, Aquahealth Sdn Bhd, to offer holistic kidney care."

UOB Kay Hian Securities (M) Sdn Bhd is the adviser and placement agent for the proposed private placement.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Topic: Press release summary
Source: Malaysian Genomics Resource Centre Berhad

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Malaysian Genomics Resource Centre Berhad Releated News
Sept 23, 2022 14:00 HKT/SGT
Malaysian Genomics Grows Presence in Thailand
Sept 21, 2022 19:00 HKT/SGT
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah
Aug 30, 2022 14:00 HKT/SGT
Malaysian Genomics Reports RM28.36 Million Full-Year Revenue
Aug 29, 2022 14:00 HKT/SGT
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region
Aug 18, 2022 18:00 HKT/SGT
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575